XKRX:326030 (Korea (the Republic of))
Â
Ordinary Shares
â‚©
86600.00
(-1.93%)
May 3
Business Description
SK Biopharmaceuticals Co Ltd
ISIN : KR7326030004
Share Class Description:
XKRX:326030: Ordinary SharesCompare
Compare
Traded in other countries / regions
326030.Korea IPO Date
2020-07-02Description
SK Biopharmaceuticals Co Ltd is a pharmaceutical company engaged in research and development of new drugs for treatment of central nervous system (CNS) disorders. The company is also researching for the development of drugs to treat brain tumors, including metastatic tumors. It has a Bio Science Research Institute in Pangyo Techno Valley in Gyeonggi Province. Its drugs in pipeline include Cenobamate, Solriamfetol, Carisbamate, Relenopride, SKL13865, SKL20540, SKL-PSY, and SKL24741.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.35 | |||||
| Equity-to-Asset | 0.39 | |||||
| Debt-to-Equity | 0.63 | |||||
| Debt-to-EBITDA | -8.79 | |||||
| Piotroski F-Score | 5/9 | |||||
| Altman Z-Score | 8.83 | |||||
| Beneish M-Score | -1.4 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 132.1 | |||||
| 3-Year EBITDA Growth Rate | 56.4 | |||||
| 3-Year EPS without NRI Growth Rate | 54.4 | |||||
| 3-Year FCF Growth Rate | 26.5 | |||||
| 3-Year Book Growth Rate | -9.2 | |||||
| Future 3-5Y Total Revenue Growth Rate | 34.53 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 55.93 | |||||
| 9-Day RSI | 51.95 | |||||
| 14-Day RSI | 48.8 | |||||
| 6-1 Month Momentum % | 14.1 | |||||
| 12-1 Month Momentum % | 29.14 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.02 | |||||
| Quick Ratio | 1.6 | |||||
| Cash Ratio | 1 | |||||
| Days Inventory | 1099.19 | |||||
| Days Sales Outstanding | 85.1 | |||||
| Days Payable | 113.07 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Shareholder Yield % | -0.91 |
Profitability Rank
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 90.4 | |||||
| Operating Margin % | -10.57 | |||||
| Net Margin % | -9.27 | |||||
| FCF Margin % | -27.46 | |||||
| ROE % | -11.01 | |||||
| ROA % | -4.8 | |||||
| ROIC % | -7.26 | |||||
| ROC (Joel Greenblatt) % | -51 | |||||
| ROCE % | -7.46 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 19.1 | |||||
| PB Ratio | 23.9 | |||||
| Price-to-Tangible-Book | 26.42 | |||||
| EV-to-EBIT | -188.84 | |||||
| EV-to-Forward-EBIT | 70.31 | |||||
| EV-to-EBITDA | -331.63 | |||||
| EV-to-Forward-EBITDA | 61.06 | |||||
| EV-to-Revenue | 18.93 | |||||
| EV-to-Forward-Revenue | 13.95 | |||||
| EV-to-FCF | -66.46 | |||||
| Price-to-Net-Current-Asset-Value | 137.74 | |||||
| Earnings Yield (Greenblatt) % | -0.53 | |||||
| FCF Yield % | -1.44 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers